GSK has licensed SiranBio’s Phase I siRNA candidate SA030, targeting ALK7 for cardiometabolic risk in metabolic and vascular disease, in a deal worth up to $1.005 billion plus royalties.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
GSK has signed a worldwide exclusive licensing agreement with Suzhou Siran Biotechnology Co., Ltd. for SA030, an investigational long-acting small interfering RNA (siRNA) therapy being developed for metabolic and vascular diseases. The agreement excludes mainland China, Hong Kong, Macau, and Taiwan.
SA030 recently entered Phase I clinical testing and targets activin receptor-like kinase 7 (ALK7), a therapeutic pathway associated with cardiometabolic disease. The companies said the candidate could address persistent cardiometabolic risk across several chronic conditions, including kidney and liver diseases.
Cardiometabolic disease remains a major cause of mortality in patients with chronic inflammatory disorders. Approximately half of patients with chronic kidney and liver disease die from cardiometabolic complications. According to the companies, ALK7 inhibition may reduce visceral adipose tissue while preserving lean muscle mass, potentially improving insulin sensitivity, lipid metabolism, and inflammation linked to fat cells.
Preclinical studies showed that SA030 demonstrated a differentiated long-acting profile with adipocyte-directed delivery and low-frequency dosing potential. The therapy is designed to target underlying inflammation associated with cardiometabolic risk. The companies also noted that SA030 has a mechanism distinct from currently approved GLP-1 agonists and SGLT2 inhibitors, which may support future combination treatment strategies.
SiranBio Founder and Chief Executive Officer Zhiwei Yang said the agreement validates the company’s extrahepatic delivery platform and siRNA pipeline. He added that GSK’s development and commercial capabilities could help accelerate the advancement of SiranBio’s therapies for obesity-related and chronic diseases.
Kaivan Khavandi, SVP, R&D Head RI&I and Head of Translational & Development Sciences at GSK, stated that cardiometabolic risk remains a major driver of mortality in patients with chronic inflammatory diseases affecting organs such as the liver, lungs, and kidneys. He said SA030 complements GSK’s broader pipeline focused on inflammation, fibrosis, and vascular disease mechanisms.
GSK said the programme will also benefit from its existing expertise in oligonucleotide therapeutics, including siRNA and antisense oligonucleotide technologies. These modalities may enable targeting of disease pathways that are difficult to address using conventional biologics or small molecules.
Under the terms of the agreement, GSK will pay SiranBio an upfront payment along with potential development, regulatory, and commercial milestone payments of up to $1.005 billion. SiranBio is also eligible to receive tiered royalties on global net sales outside the licensed territories.
SiranBio will continue leading clinical development of SA030 through completion of Phase I studies. Following Phase I, GSK will assume responsibility for global development, regulatory submissions, and commercialization outside mainland China, Hong Kong, Macau, and Taiwan.
Reference
About the Writer
Samiksha Vikram Jadhav (LinkedIn) is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She specializes in pharma market research, with a focused interest in mergers and acquisitions, strategic partnerships, and global pharma and biotech deals. Her work centers on analyzing industry transactions, market positioning, and business strategies, translating complex developments into clear, accurate, and insightful scientific and commercial reporting.